Galectin Therapeutics (GALT) EPS Estimated At $-0.13, Wasatch Advisors Cut Anadarko Petroleum Corp. (APC) Holding

July 24, 2017 - By Stephen Andrade

Wasatch Advisors Inc decreased Anadarko Petroleum Corp. (APC) stake by 48.54% reported in 2016Q4 SEC filing. Wasatch Advisors Inc sold 92,789 shares as Anadarko Petroleum Corp. (APC)’s stock declined 20.17%. The Wasatch Advisors Inc holds 98,357 shares with $6.86 million value, down from 191,146 last quarter. Anadarko Petroleum Corp. now has $24.81B valuation. The stock increased 0.50% or $0.22 on July 21, reaching $44.06. About shares traded. Anadarko Petroleum Corporation (NYSE:APC) has risen 8.29% since July 24, 2016 and is uptrending. It has underperformed by 8.41% the S&P500.

Analysts expect Galectin Therapeutics Inc (NASDAQ:GALT) to report $-0.13 EPS on August, 14 before the open.They anticipate $0.07 EPS change or 35.00% from last quarter’s $-0.2 EPS. After having $-0.15 EPS previously, Galectin Therapeutics Inc’s analysts see -13.33% EPS growth. It closed at $2.18 lastly. It is down 62.09% since July 24, 2016 and is uptrending. It has outperformed by 45.39% the S&P500.

Among 37 analysts covering Anadarko Petroleum Corporation (NYSE:APC), 28 have Buy rating, 2 Sell and 7 Hold. Therefore 76% are positive. Anadarko Petroleum Corporation had 84 analyst reports since July 21, 2015 according to SRatingsIntel. Macquarie Research maintained the shares of APC in report on Wednesday, September 14 with “Outperform” rating. Jefferies maintained Anadarko Petroleum Corporation (NYSE:APC) rating on Monday, May 1. Jefferies has “Buy” rating and $62 target. The rating was upgraded by Deutsche Bank on Thursday, October 13 to “Buy”. The company was upgraded on Wednesday, November 2 by Credit Suisse. On Tuesday, March 29 the stock rating was maintained by Deutsche Bank with “Hold”. The company was upgraded on Thursday, December 1 by Stifel Nicolaus. The company was downgraded on Thursday, November 12 by Tudor Pickering. The stock has “Hold” rating by Deutsche Bank on Thursday, January 7. The firm has “Buy” rating by Ladenburg Thalmann given on Monday, December 19. The company was downgraded on Tuesday, January 3 by Raymond James.

Wasatch Advisors Inc increased Red Lion Hotels Corp (NYSE:RLH) stake by 110,000 shares to 210,000 valued at $1.75M in 2016Q4. It also upped Alphabet Inc. stake by 2,193 shares and now owns 5,985 shares. Makemytrip Ltd. (NASDAQ:MMYT) was raised too.

Investors sentiment decreased to 1.22 in Q4 2016. Its down 0.13, from 1.35 in 2016Q3. It turned negative, as 59 investors sold APC shares while 242 reduced holdings. 89 funds opened positions while 278 raised stakes. 472.75 million shares or 0.09% more from 472.34 million shares in 2016Q3 were reported. 10,266 are owned by National Registered Investment Advisor. Peak6 Invests Limited Partnership holds 81,135 shares. Bnp Paribas Invest Prtnrs invested in 0.18% or 266,725 shares. Kistler stated it has 425 shares or 0.01% of all its holdings. Brown Brothers Harriman & owns 8,946 shares for 0% of their portfolio. Beck Mack And Oliver Llc reported 0.02% stake. Intact Inv Mngmt Inc holds 0.04% of its portfolio in Anadarko Petroleum Corporation (NYSE:APC) for 13,700 shares. Cognios Ltd Com invested in 0.87% or 40,908 shares. Moreover, Benjamin F Edwards And Inc has 0.1% invested in Anadarko Petroleum Corporation (NYSE:APC). Fil Ltd holds 0.06% or 314,416 shares in its portfolio. 5,230 were reported by Winslow Evans & Crocker. Murphy Cap Mngmt accumulated 0.08% or 7,075 shares. California-based Meridian Inv Counsel has invested 0.2% in Anadarko Petroleum Corporation (NYSE:APC). Advantus Capital Management invested in 55,936 shares or 0.1% of the stock. Intrust Retail Bank Na reported 0.37% of its portfolio in Anadarko Petroleum Corporation (NYSE:APC).

Since May 17, 2017, it had 3 buys, and 0 sales for $2.14 million activity. On Wednesday, May 17 the insider FLUOR PETER J bought $1.04M. WALKER R A had bought 19,300 shares worth $1.00M on Wednesday, May 17. $99,967 worth of Anadarko Petroleum Corporation (NYSE:APC) shares were bought by CHASE ANTHONY R.

Investors sentiment increased to 0.83 in Q4 2016. Its up 0.28, from 0.55 in 2016Q3. It improved, as 7 investors sold Galectin Therapeutics Inc shares while 5 reduced holdings. 2 funds opened positions while 8 raised stakes. 2.41 million shares or 4.93% less from 2.53 million shares in 2016Q3 were reported. Tci Wealth reported 0% in Galectin Therapeutics Inc (NASDAQ:GALT). California Public Employees Retirement accumulated 23,450 shares. Wolverine Asset Ltd Company reported 0% in Galectin Therapeutics Inc (NASDAQ:GALT). Benchmark Capital Advsrs accumulated 0.16% or 198,200 shares. Next Fin Grp Inc reported 1,000 shares stake. Vanguard Grp Inc has invested 0% in Galectin Therapeutics Inc (NASDAQ:GALT). Courage Capital Mgmt Ltd Llc owns 130,000 shares. Moreover, Royal Bank Of Canada has 0% invested in Galectin Therapeutics Inc (NASDAQ:GALT). Creative Planning holds 0% of its portfolio in Galectin Therapeutics Inc (NASDAQ:GALT) for 488 shares. Wells Fargo Com Mn holds 0% or 4,720 shares in its portfolio. Cutter Company Brokerage has 36,000 shares. State Street Corp accumulated 11,450 shares or 0% of the stock. Bank Of New York Mellon holds 0% in Galectin Therapeutics Inc (NASDAQ:GALT) or 21,950 shares. Morgan Stanley reported 6,463 shares. Blackrock Inv Management Ltd Co reported 0% stake.

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical firm engaged in drug research and development to create therapies for fibrotic disease and cancer. The company has market cap of $75.21 million. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It currently has negative earnings. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties.

Among 4 analysts covering Galectin Therapeutics (NASDAQ:GALT), 1 have Buy rating, 2 Sell and 1 Hold. Therefore 25% are positive. Galectin Therapeutics had 8 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was downgraded by TH Capital to “Sell” on Wednesday, September 28. The stock has “Buy” rating by H.C. Wainwright on Monday, March 28. H.C. Wainwright upgraded the shares of GALT in report on Thursday, March 30 to “Buy” rating. As per Thursday, September 29, the company rating was downgraded by H.C. Wainwright. The firm has “Mkt Perform” rating by FBR Capital given on Monday, October 3. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 21. Roth Capital downgraded Galectin Therapeutics Inc (NASDAQ:GALT) on Wednesday, September 28 to “Sell” rating. H.C. Wainwright maintained Galectin Therapeutics Inc (NASDAQ:GALT) rating on Wednesday, June 14. H.C. Wainwright has “Buy” rating and $3.5000 target.

Since May 23, 2017, it had 1 buy, and 0 insider sales for $2,270 activity. ZUCCONI THEODORE DANIEL bought $2,270 worth of Galectin Therapeutics Inc (NASDAQ:GALT) on Tuesday, May 23.